CGTX
Cognition Therapeutics, Inc.
Biotechnology
Market Cap$91M
5Y Perf.-89.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
CGTX vs SAVA
Revenue, margins, valuation, and 5-year total return — side by side.
SAVA
Cassava Sciences, Inc.
Biotechnology
Market Cap$94M
5Y Perf.-63.0%
CGTX vs SAVA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CGTX | SAVA |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $91M | $94M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-23M | $-106M |
| Total Debt | $638K | $0.00 |
| Cash & Equiv. | $37M | $129M |
CGTX vs SAVA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CGTX
SAVA
| Stock | Oct 21 | May 26 | Return |
|---|---|---|---|
| Cognition Therapeut… (CGTX) | 100 | 10.2 | -89.8% |
| Cassava Sciences, I… (SAVA) | 100 | 37.0 | -63.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CGTX vs SAVA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CGTX leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. Cassava Sciences, Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
CGTX
Cognition Therapeutics, Inc.
The Growth Leader
CGTX carries the broadest edge in this set and is the clearest fit for growth and momentum.
- 31.0% revenue growth vs SAVA's -5.4%
- +194.6% vs SAVA's +29.5%
- -69.6% ROA vs SAVA's -75.3%
Best for: growth and momentum
SAVA
Cassava Sciences, Inc.
The Income Pick
SAVA is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 1 yrs, beta 2.02
- EPS growth 77.6%
- -18.5% 10Y total return vs CGTX's -90.4%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CGTX | 31.0% revenue growth vs SAVA's -5.4% |
| Quality / Margins | SAVA | 5.4% margin vs CGTX's -0.0% |
| Stability / Safety | SAVA | Beta 2.02 vs CGTX's 3.40 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CGTX | +194.6% vs SAVA's +29.5% |
| Efficiency (ROA) | CGTX | -69.6% ROA vs SAVA's -75.3% |
CGTX vs SAVA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSAVALAGGINGCGTX
CGTXCognition Therapeutic…
1leads
SAVACassava Sciences, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs CGTXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CGTX1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SAVA4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
SAVA2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CGTX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
CGTX and SAVA operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | CGTXCognition Therape… | SAVACassava Sciences,… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$48M | -$110M |
| Net IncomeAfter-tax profit | -$23M | -$106M |
| Free Cash FlowCash after capex | -$25M | -$84M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +77.9% | +62.1% |
CGTX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — CGTX and SAVA each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | CGTXCognition Therape… | SAVACassava Sciences,… |
|---|---|---|
| Market CapShares × price | $91M | $94M |
| Enterprise ValueMkt cap + debt − cash | $54M | -$34M |
| Trailing P/EPrice ÷ TTM EPS | -3.84x | -3.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 2.61x | 0.63x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — CGTX and SAVA each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
SAVA leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
SAVA delivers a -95.8% return on equity — every $100 of shareholder capital generates $-96 in annual profit, vs $-104 for CGTX. On the Piotroski fundamental quality scale (0–9), CGTX scores 3/9 vs SAVA's 2/9, reflecting mixed financial health.
| Metric | CGTXCognition Therape… | SAVACassava Sciences,… |
|---|---|---|
| ROE (TTM)Return on equity | -104.3% | -95.8% |
| ROA (TTM)Return on assets | -69.6% | -75.3% |
| ROICReturn on invested capital | — | -6.3% |
| ROCEReturn on capital employed | -178.5% | -99.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | 0.02x | — |
| Net DebtTotal debt minus cash | -$36M | -$129M |
| Cash & Equiv.Liquid assets | $37M | $129M |
| Total DebtShort + long-term debt | $638,000 | $0 |
| Interest CoverageEBIT ÷ Interest expense | -2600.54x | — |
SAVA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — CGTX and SAVA each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SAVA five years ago would be worth $3,275 today (with dividends reinvested), compared to $963 for CGTX. Over the past 12 months, CGTX leads with a +194.6% total return vs SAVA's +29.5%. The 3-year compound annual growth rate (CAGR) favors CGTX at -8.6% vs SAVA's -16.0% — a key indicator of consistent wealth creation.
| Metric | CGTXCognition Therape… | SAVACassava Sciences,… |
|---|---|---|
| YTD ReturnYear-to-date | -16.3% | -6.5% |
| 1-Year ReturnPast 12 months | +194.6% | +29.5% |
| 3-Year ReturnCumulative with dividends | -23.6% | -40.8% |
| 5-Year ReturnCumulative with dividends | -90.4% | -67.3% |
| 10-Year ReturnCumulative with dividends | -90.4% | -18.5% |
| CAGR (3Y)Annualised 3-year return | -8.6% | -16.0% |
Evenly matched — CGTX and SAVA each lead in 3 of 6 comparable metrics.
Risk & Volatility
SAVA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
SAVA is the less volatile stock with a 2.02 beta — it tends to amplify market swings less than CGTX's 3.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SAVA currently trades 39.3% from its 52-week high vs CGTX's 32.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CGTXCognition Therape… | SAVACassava Sciences,… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 3.40x | 2.02x |
| 52-Week HighHighest price in past year | $3.83 | $4.98 |
| 52-Week LowLowest price in past year | $0.22 | $1.45 |
| % of 52W HighCurrent price vs 52-week peak | +32.1% | +39.3% |
| RSI (14)Momentum oscillator 0–100 | 59.2 | 46.8 |
| Avg Volume (50D)Average daily shares traded | 1.2M | 720K |
SAVA leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates CGTX as "Buy" and SAVA as "Buy".
| Metric | CGTXCognition Therape… | SAVACassava Sciences,… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | 7 | 12 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
SAVA leads in 2 of 6 categories (Profitability & Efficiency, Risk & Volatility). CGTX leads in 1 (Income & Cash Flow). 2 tied.
Best OverallCassava Sciences, Inc. (SAVA)Leads 2 of 6 categories
Loading custom metrics...
CGTX vs SAVA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is CGTX or SAVA a better buy right now?
Analysts rate Cognition Therapeutics, Inc.
(CGTX) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CGTX or SAVA?
Over the past 5 years, Cassava Sciences, Inc.
(SAVA) delivered a total return of -67. 3%, compared to -90. 4% for Cognition Therapeutics, Inc. (CGTX). Over 10 years, the gap is even starker: SAVA returned -18. 5% versus CGTX's -90. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CGTX or SAVA?
By beta (market sensitivity over 5 years), Cassava Sciences, Inc.
(SAVA) is the lower-risk stock at 2. 02β versus Cognition Therapeutics, Inc. 's 3. 40β — meaning CGTX is approximately 68% more volatile than SAVA relative to the S&P 500.
04Which is growing faster — CGTX or SAVA?
On earnings-per-share growth, the picture is similar: Cassava Sciences, Inc.
grew EPS 77. 6% year-over-year, compared to 62. 4% for Cognition Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CGTX or SAVA?
Cognition Therapeutics, Inc.
(CGTX) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Cassava Sciences, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CGTX leads at 0. 0% versus 0. 0% for SAVA. At the gross margin level — before operating expenses — CGTX leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — CGTX or SAVA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is CGTX or SAVA better for a retirement portfolio?
For long-horizon retirement investors, Cassava Sciences, Inc.
(SAVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Cognition Therapeutics, Inc. (CGTX) carries a higher beta of 3. 40 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SAVA: -18. 5%, CGTX: -90. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CGTX and SAVA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.